Common use of Terms Defined Elsewhere Clause in Contracts

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Agreement Preamble Antitrust Approvals 4.3(b) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) Xxxx of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) 68 Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b) Material Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(a) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(ii)

Terms Defined Elsewhere. The following is a list of additional terms are defined elsewhere used in this Agreement, as indicated belowAgreement and a reference to the Section hereof in which such term is defined: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(bTerm Section Acquisition Sub Preamble Acquisition Sub Company Common Stock 2.8(c) Agreement Preamble Antitrust Approvals 4.3(b) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) Xxxx of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(bLaws 5.5 Certificates 2.10(b) Closing 1.3(a2.3(a) Closing Adjustment 2.14(b) Closing Cash 2.14(a) Closing Cash Target 2.14(a) Closing Consideration Allocation Schedule 2.9(c) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a2.3(a) COBRA 9.3(fCoverage 3.12(e) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(bCollective Bargaining Agreement 3.17(a) Company Preamble Company Assets 3.5 Company Bylaws 2.3(c)(ii) Company Disclosure Schedule Article III: Preamble Company-Owned Intellectual Property 3.18(a) Company Stockholder Approval 3.3(b) Company Warrants 3.4(c) Term Section Confidentiality Agreement 4.2 Contingent Payment 1.2(b5.4(d) CTAs 2.9(bCopyrights 3.18(a) Damages 6.1 DOJ DGCL 4.3(a) Domain Name Assignment Agreement 1.3(b)(viDissenting Shares 2.12 DOJ 5.5(b) Downward Adjustment Amount 1.4(c)(iEarly Termination Election 7.1(c) Draft Allocation 8.5 Electronic Delivery 10.7 Early Termination Override Notice 7.1(c) Effective Time 2.2 Employee Benefit Plan 2.16(aPlans 3.12(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(aAgreements 2.3(b)(iv) Estimated Net Working Capital 1.2(eClosing Cash 2.14(b) 68 Excluded Assets 1.1(bExchange Act 4.5(a) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(aFCPA 3.25(a) FTC 4.3(a5.5(b) Fundamental Representations 6.4(aGeneral Enforceability Exceptions 3.3(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(bIn-Bound License Agreements 3.6(a)(v) Indemnified Party 6.3(aOfficers 5.7(a) Indemnifying Party 6.3(aInfringes 3.18(d) Inquiry 4.7(aInsurance 3.19 Intellectual Property 3.18(a) IP Assignment Agreements 1.3(b)(viiLetter of Transmittal 2.10(b) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b3.6(a)(v) Material Contract 2.10(aContracts 3.6(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(aMerger 2.1 Merger Certificate 2.2 Money Laundering Laws 3.25(b) Multi-Employer Plan 3.12(a) Non-Compete Period 9.9(aUnion Employees 5.8(a) NonNRS 2.1 Out-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(iBound License Agreements 3.6(a)(v) Outside Date 7.1(d)(ii7.1(b) Parties Parent Preamble Parent SEC Documents 4.5(a) Parent Stockholder Approval 4.3(b) Party Preamble Patent Assignment Agreement 1.3(b)(vRepresentative 5.2(a) Permits 1.1(a)(ivPatents 3.18(a) Payoff Letter 2.9(b) Pre-Closing Taxes 3.10(a) Real Property Leases 3.7(a) Real Property Permits 3.7(g) Record Retention Period 4.1(a5.12 Representative Preamble Requested Information 5.4(b) Registered Business IP 2.9(aTerm Section Xxxxxxxx-Xxxxx Act 4.5(a) Regulatory Authority 2.13(bSEC 4.5(a) Regulatory Filings 4.3(aSecurities Act 4.5(a) Reimbursement Amount 9.4(cSettlement Accountants 2.13(e) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(dSoftware 3.18(a) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(aSpecial Meeting 5.3(e) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(gStock Plan 3.4(b) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(aSurviving Corporation 2.1 Systems 3.18(o) Third Party IP 2.9(bIntellectual Property 3.18(b) Trademark Assignment Agreement 1.3(b)(viiTrade Secrets 3.18(a) Transfer Taxes 8.1(aTrademarks 3.18(a) Transferred Accounts Receivable 1.1(a)(xivTransaction Fee Statement 2.9(a) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiWARN Act Laws 3.17(d)

Terms Defined Elsewhere. The Each of the following terms are defined elsewhere has the meaning ascribed to such term in this Agreement, as indicated belowthe Article or Section set forth opposite such term: 2017 Bonuses 9.3(aTerm Article/Section Acquired Company; Acquired Companies 3.3(b) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Acquisition Proposal 6.6 Agreement Preamble Antitrust Approvals 4.3(bAllocation Statement 7.3(i) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) Xxxx of Sale 1.3(b)(iiiLimitation Date 7.1 Basket 7.2(c) Business Benefit Plans 2.16(a) Business Employee 9.3(aRelation 7.7(b) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(bCap 7.2(c) Closing 1.3(a) 2.3 Closing Date 1.3(a) 2.3 Closing Net Working Capital 1.4(aEstimate Statement 2.2 Closing Items 2.4(a) Closing Statement 1.4(a2.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Company Preamble Company IP 3.11 Company Employee Benefit Plan 2.16(a3.16(a) Employment Practices 2.15(bDispute Notice 2.4(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Effective Date Preamble Estimated Net Indebtedness 2.2 Estimated Foreign Withholding Amounts 2.2 Estimated Working Capital 1.2(e2.2 Excess Amount 2.4(c) 68 Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(bFinancial Statements 3.4(a) Final Allocation 8.5 Indebtedness 2.4(a) Final Net Working Capital 1.4(b)(ivForeign Withholding Amounts 2.4(a) FSA Balances 9.3(aImprovements 3.7 Indemnitee 7.2(g) FSA Participants 9.3(aIndemnitor 7.2(g) FTC 4.3(aIRS 3.16(b) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(ivXxxxx Preamble Latest Balance Sheet 3.4(a) Lease 2.8(b) 3.7 Leased Real Property 2.8(b) 3.7 Material Contract 2.10(a3.10(b) Material Customers 2.11 3.21 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Vendors 3.21 Monroe Preamble Outside Date 7.1(d)(ii8.1(c) Parties Parent Preamble Party Preamble Patent Assignment Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Tax Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a7.3(a) Straddle Period 8.1(b)(i7.3(c) Sublease 1.3(b)(xiPurchased Units Recitals Term Article/Section Restricted Business 7.7(a) Supply Agreements 4.6 Restricted Period 7.7(a) Resolution Period 2.4(b) Sellers Preamble Seller Parties Preamble Subsidiaries 3.3(b) Shortfall Amount 2.4(c) Tax Claim 8.4 Third Contest 7.3(d) Terminating Party Claim 6.3(a8.1(b) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(ii)Xxxx Preamble Units Recitals

Terms Defined Elsewhere. The In addition to the terms defined in Section 1.1, each of the following terms are is defined elsewhere in this Agreement, as indicated belowthe Section set forth opposite such term: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Term Section Agreement Preamble Antitrust Approvals 4.3(bAssumption Agreement 4.2(a)(ii) Applicable Cap Amount 6.5(b)(i) Assigned Assets 2.2 Assumed Contracts 1.1(a)(iii2.2(b) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) 2.4 Audits 5.6 Xxxx of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a4.2(a)(i) Buyer Preamble Buyer FDA Letters 5.3(dCap 8.6(b) Buyer Group 1.1(a) Parties 8.1 Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Losses 8.1 Claim Notice 6.3(b) Claimed Amount 6.3(b) 8.3 Claims Period 8.7 Closing 1.3(a) Closing 4.1 Confidential Information 7.4 Effective Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) 68 Preamble Excluded Assets 1.1(b2.3 Excluded Contracts 2.5(c) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) 2.5 Leased Real Property 2.8(b5.10(b) Material Contract 2.10(aContracts 5.10(c) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(aOffer of Employment 7.2(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(iiOpen Source Materials 5.11(n) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(v) Permits 1.1(a)(ivPersonal Property Leases 5.10(a) Pre-Closing Period 4.1(aReceivables 2.2(g) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(cProposed Contract 4.3 Real Property Leases 5.10(b) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(dParty 5.19(a) Secured Notes 4.5 Response Period 8.4(a) Required Approvals 4.3 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(aCap 8.6(a) Seller Disclosure Letter Article II 69 Insurance Policies 5.12 Seller FDA Letters 5.2(g) Parties 8.2 Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Losses 8.2 Third Party Claim 6.3(aAction 8.4(a) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(aAction Notice 8.4(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiEmployee 7.3(a)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Term Section Agreement Preamble Antitrust Approvals Board Observer 5.3(b) Company Preamble Confidential Information 5.2(a) Corporate Opportunity Party 5.7 Demand 4.1(a) Demand Registration 4.1(a) Drag Notice 3.7(b) Drag-Along Sale 3.7(a) Dragged Shareholders 3.7(a) Dragging Shareholders 3.7(a) Excess Shares 2.1(c) Executive Transfer 3.2(c) Family Member 3.2(b) Form S-3 Registration Statement 4.3(b) Applicable Cap Amount 6.5(b)(iForm S-3 Shelf Registration Statement 4.3(b) Assigned Contracts 1.1(a)(iiiFully Participating Shareholder 2.1(c) Assumed Liabilities 1.1(cInitial Exercise Period 3.5(b) Assumption Agreements 1.1(cInitial Purchaser 2.1(g) Xxxx of Sale 1.3(b)(iiiInitiating Shelf Holder 4.4(a) Business Benefit Plans 2.16(aIPO Holdback Period Appendix Legend 6.1 Marketed Underwritten Shelf Take-Down 4.4(b) Business Employee 9.3(aNew Issuance 2.1(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim New Issuance Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) 68 Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b) Material Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a2.1(a) Non-Compete Period 9.9(aElecting Shares 3.6(d) Non-Contingent Bonuses 9.3(cMarketed Underwritten Shelf Take-Down 4.4(c) Non-Solicit Period 9.9(bMarketed Underwritten Shelf Take-Down Notice 4.4(d) Objection Notice 1.4(b)(iRecipient 4.4(d) Outside Date 7.1(d)(iiOffer Notice 3.5(a) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(vOffer Price 3.5(a) Permits 1.1(a)(ivOffered Securities 2.1(a) PreOffered Tag-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(a) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiAlong Sale Shares 3.6(b)

Terms Defined Elsewhere. The In addition to the terms defined in Section 1.1, each of the following terms are is defined elsewhere in this Agreement, as indicated belowthe Section set forth opposite such term: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Term Section Agreement Preamble Antitrust Approvals 4.3(bAnnual Financials 5.5(a) Applicable Cap Amount 6.5(b)(i) Assigned Assets 2.2 Assumed Contracts 1.1(a)(iii2.2(b) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c2.4 Basket Amount 8.5(c) Xxxx of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a4.2(a)(i) Buyer Preamble Buyer FDA Letters 5.3(d) Parties 8.1 Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(aClosing Certificate 4.2(b)(vii) Claim Notice 6.3(b) Claimed Amount 6.3(b8.3 Claims Period 8.5(a) Closing 1.3(a) 4.1 Closing Date 1.3(a2.1 De Minimis Investment 5.16(a) Closing Net Working Capital 1.4(aEffective Date Preamble Employee Services Agreement 4.2(a)(ii) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) 68 Excluded Assets 1.1(b2.3 Excluded Contracts 2.5(c) Excluded Liabilities 1.1(d2.5 Financial Statements 5.5(a) FDA 2.13(bHSRL Loan 4.2(a)(x) Final Allocation 8.5 Final Net Working Capital 1.4(b)(ivInterim Balance Sheet 5.5(a) FSA Balances 9.3(aTerm Section Interim Financials 5.5(a) FSA Participants 9.3(aLicense Agreements 5.10(a)(x) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(bLien Releases 4.2(a)(x) Material Contract 2.10(aContracts 5.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(iiParent Preamble Parent Stockholder Claim 8.1(d) Parties Preamble Payoff Letters 4.2(a)(ix) Purchase Price 3.1 Related Party Preamble Patent Assignment Agreement 1.3(b)(v5.16(a) Permits 1.1(a)(ivResponse Period 8.4(a) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(aInsurance Policies 5.12(a) Seller Disclosure Letter Article II 69 Parties 8.2 Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(aClosing Certificate 4.2(a)(iv) Third Party IP 2.9(bAction 8.4(a) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xiThird Party Action Notice 8.4(a) Transferred IP 1.1(a)(iv2.2(c) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiEmployees 7.2(a)

Terms Defined Elsewhere. The following terms are defined elsewhere As used in this Agreement, the following capitalized terms are defined in this Agreement as indicated belowreferenced in the following table: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Definition Location Agreement Preamble Antitrust Approvals 4.3(bBylaws 3.2 Capitalization Date 5.2(a) Applicable Cap Amount 6.5(b)(iChange of Recommendation 7.2(d)(i)(F) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) Xxxx of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Charter 3.1 Closing 1.3(a) 2.1 Closing Date 1.3(a2.1 Company Preamble Company Approvals 5.4(a) Closing Net Working Capital 1.4(aCompany Disclosure Letter Article V Company Personal Information 5.18(l) Closing Statement 1.4(aCompany Recommendation 5.3(b) COBRA 9.3(fCompany Tax Representation Letter 7.18(c) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(bContinuation Period 7.11(a) Confidentiality Agreement 4.2 Contingent Payment 1.2(bD&O Insurance 7.12(b) CTAs 2.9(bDelisting Period 7.17(a) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) 68 Excluded Assets 1.1(b) Excluded Liabilities 1.1(dEffective Time 2.2 Exchange Fund 4.3(a)(i) FDA 2.13(b5.20(a) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(aFDA Licenses 5.20(a) Fundamental Representations 6.4(aAction 7.2(d)(iii) Governmental Antitrust Entity 2.4(b7.6(b)(ii) Hazardous Substances 2.19 Healthcare Laws 2.13(aInterim Period 7.1(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(bLegal Restraint 8.1(c) Material Contract 2.10(a5.11(a) Material Customers 2.11 Customer 5.12(a) Material Suppliers 2.11 New Buyer Employee 9.3(aVendor 5.12(b) Merger Recitals Merger Sub Preamble Non-Compete Wholly Owned Subsidiary 5.2(f) Notice of Redemption 7.13(a) Notice 7.2(d)(iii) Notice Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i7.2(d)(iii) Outside Date 7.1(d)(ii9.2(a) Parent Preamble Parent Approvals 6.4(a) Parent DSU 4.2(f) Parent Option 4.2(a) Parent RSU 4.2(c) Parent Tax Representation Letter 7.18(c) Parent SAR 4.2(e) Parties Preamble Party Preamble Patent Assignment Permitted Confidentiality Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(aPotential Purchasers 7.6(d) Specified Milestone Payment 9.4(aPotential Sale Transaction 7.6(d) Straddle Period 8.1(b)(iPrivacy and Security Measures 5.18(k) Sublease 1.3(b)(xiPrivacy-Related Contracts 5.11(a)(vi) Supply Agreements 4.6 Proxy Statement 7.3(a) Definition Location Stock Ownership Rep 6.8 Support Agreement Recitals Surviving Corporation 2.3 Tax Claim 8.4 Third Representation Letters 7.18(c) Third-Party Claim 6.3(aConsents 7.8 Transaction Litigation 7.15 TRA Terminations 7.13(d) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiVote-Down 9.2(b)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement. For purposes of this Agreement, as indicated belowthe following terms have the meanings set forth in the sections indicated: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Term Section Agreement Preamble Antitrust Approvals 4.3(bAssignment and Assumption 2.5(a)(v) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) Xxxx of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Bothell Property 2.10 Bothell ROFR Property 2.10 Bothell Safeway Property 2.10 Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a6.2(a) California Real Property 8.3(a) CAM Changes 2.6(a)(i) Claim Notice 6.3(b) Claimed Amount 6.3(b6.3(a) Closing 1.3(a2.4 Closing Date 2.4 Closing Sales Tax 2.8(c) Closing Date 1.3(a) Closing Net Working Capital 1.4(aSales Tax Forms 2.8(c) Closing Statement 1.4(a2.5(a)(xiv) COBRA 9.3(fCode 2.11 Cost-to-Complete Budget True-up Amount 2.7(c) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(bCost-to-Complete Settlement Statement 2.7(a) Confidentiality Current Year Tax Appeal 2.6(a) Data Room 6.5(b) Deed 2.5(a)(i) Deposit Escrow Agreement 4.2 Contingent Payment 1.2(b7.6 Development Plans 3.13 Disclosing Party 5.4(c) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(iDistrict LUEs 8.7(b) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(aXxxxx XXX Definition of Xxxxx XXX ESPM 8.3(b) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) 68 Excluded Exchanged Transferred Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(b5.11(a) Final Allocation 8.5 Adjustment 2.7(c) Final Net Working Capital 1.4(b)(ivProration Period 2.6(b) FSA Balances 9.3(aFinal Proration Settlement Statement 2.6(b) FSA Participants 9.3(aFinal Purchase Price 2.2 Guaranty Cap 7.10(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(bGround Lease Assignment 2.5(a)(i) Indemnified Party 6.3(a) Indemnifying Party Initial Deposit 6.3(a) Inquiry 4.7(a7.6 Initial Purchase Price 2.2 Leases 3.4(e) IP Assignment Agreements 1.3(b)(viiLicensed Website Content 5.2 LUEs 8.7(b) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b) Material Minor Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a3.6(b) Non-Compete Period 9.9(aParty Affiliate 6.7(d) Non-Contingent Bonuses 9.3(cOccasional Sale Certificate 2.8(b) Non-Solicit Period 9.9(bPDC Office Lease 2.5(a)(vii) Objection Potential Contributor 6.4(f) Prorated Items 2.6(a) QI 5.11(a) RCW 8.9 Receiving Party 5.4(c) Referee Reference Commencement Notice 1.4(b)(iReference Stipulation 7.11 7.11 7.11 Released Claims 6.5(d) Outside Date 7.1(d)(iiRequired Estoppels 2.5(a)(xvi) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(vRequired Tenant Waivers 2.5(a)(xv) Permits 1.1(a)(ivSafeway Marks 5.2 Sales Tax 2.8(c) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Disclosure Statement 8.9 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Seller FSA 9.3(aGuaranteed Obligations 7.10(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v6.2(b) Seller SEC Documents Article II Marks 5.2 Seller Termination Fee 7.2(b)(iParent Preamble Seller Tenant Certificate 2.5(a)(xvii) Seller Trademarks 9.6 Shire Milestone Payment 9.4(aSurveys 2.9(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Third-Party Claim 6.3(a) Third Party IP 2.9(bTitle Commitment 2.9(a) Trademark Assignment Agreement 1.3(b)(viiTitle Company 2.9(a) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements Title Notice 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Assets Recitals Transition Services Agreement 1.3(b)(x2.5(a)(vi) Upfront Payment 1.2(aTrue-up Accountant 2.6(b) Upward Adjustment True-up Amount 1.4(c)(iiTrue-up Covenant 2.6(b) 6.4(a) Unresolved Cost-to-Complete Items 2.7(c) Unresolved Items 2.6(b) Year-End 2.6(6)(i)

Terms Defined Elsewhere. The following terms are defined elsewhere As used in this Agreement, the following capitalized terms are defined in this Agreement as indicated belowreferenced in the following table: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Definition Location Agreement Preamble Antitrust Approvals 4.3(bAnti-Corruption Laws 5.5(d) Applicable Cap Amount 6.5(b)(iBylaws 3.2 Change of Recommendation 7.2(d)(i)(G) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) Xxxx of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Charter 3.1 Closing 1.3(a) 2.1 Closing Date 1.3(a2.1 Company Preamble Company Approvals 5.4(a) Closing Net Working Capital 1.4(aCompany Disclosure Letter Article V Company Personal Information 5.18(l) Closing Statement 1.4(aCompany Recommendation 5.3(b) COBRA 9.3(fD&O Insurance 7.12(a) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(bDelisting Period 7.18(a) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) 68 Excluded Assets 1.1(bEffective Time 2.2 Exchange Fund 4.3(a)(i) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(aShare 4.1(b) Governmental Antitrust Entity 2.4(b7.6(b)(ii) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(ivInterim Period 7.1(a) Lease 2.8(b5.17(a) Leased Real Property 2.8(bLegal Restraint 8.1(c) Material Contract 2.10(a5.11(a)(xvi) Material Customers 2.11 Payor 5.12(a) Material Suppliers 2.11 New Buyer Employee 9.3(aVendor 5.12(b) Merger Recitals Merger Consideration 4.1(a) Merger Sub Preamble Non-Compete Wholly Owned Subsidiary 5.2(f) Notice 7.2(d)(iii) Notice Period 9.9(a7.2(d)(iii) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(iOriginal Date 7.4(b) Outside Date 7.1(d)(ii9.2(a) Parent Preamble Parent Approvals 6.4(a) Parent Option 4.2(a)(ii) Parent RSA 4.2(b) Parties Preamble Party Preamble Patent Assignment Permitted Confidentiality Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(aPotential Purchasers 7.6(d) Specified Milestone Payment 9.4(aPotential Sale Transaction 7.6(d) Straddle Period 8.1(b)(iPrivacy and Security Requirements 5.18(k) Sublease 1.3(b)(xiProxy Statement 7.3(a) Supply Agreements 4.6 Tax Claim 8.4 Third Subsidiary Partnership 5.16(o) Surviving Corporation 2.3 Third-Party Claim 6.3(a) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(ii)Consents 7.8 Transaction Litigation 7.15

Terms Defined Elsewhere. The following terms are defined elsewhere in For purposes of this Agreement, as indicated belowthe following terms have the meanings set forth in the sections indicated: 2017 Bonuses 9.3(aTerm Section 401(k) Acquired Assets 1.1(aTermination Date 7.13(d) Accounting Firm 7.18(h) Action 7.10(a) Aggregate Threshold 6.5(b)(ii) Agreed Equity Election Amount 6.3(b3.1(c)(i) Agreement Preamble All Equity Exchange Ratio 3.1(c)(i)(B) Alternative Proposal 7.3(i)(i) Amended Parent Opco Limited Partnership Agreement 2.1(e) Antitrust Approvals 4.3(bLaws 7.1(a) Applicable Cap Antitrust Remedies 7.1(b) Available Cash Amount 6.5(b)(i3.1(c)(i) Assigned Contracts 1.1(a)(iiiAvailable Equity Amount 3.1(c)(i) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) Xxxx of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b5.9(a) Confidentiality Book-Entry Units 3.2(c) Cash Election 3.3(a) Cash Election Consideration 3.1(c)(i)(A) Cash Election Units 3.1(c)(i)(A) Certificate 3.2(c) Certificate of GP Merger 1 2.1(d) Certificate of GP Merger 2 2.1(d) Certificate of LP Merger 2.1(d) Certificates of Merger 2.1(d) Claim 7.10(a) Closing 2.2 Closing Date 2.2(b) Code Recitals Continuing Employees 7.13(a) Continuing Partnership 7.18(c) 16 EGP Preamble Election 3.3(a) Election Deadline 3.3(c) Election Form 3.3(c) Election Form Record Date 3.3(c) Exchange Agent 3.3(b) Exchange Fund 3.4(a) Excluded Partnership Unit 3.1(c)(i) Financial Advisor 7.3(b) Financing 7.17(a) Financing Related Parties 10.14 Financing Sources 10.14 GP Merger 1 Recitals GP Merger 1 Consideration 3.1(a) GP Merger 1 Effective Time 2.1(d) GP Merger 2 Recitals GP Merger 2 Consideration 3.1(b) GP Merger 2 Effective Time 2.1(d) GP Merger Consideration Allocation 7.18(h) GP Mergers Recitals GP Pre-Closing Distribution 7.23 GP Written Consents 7.16 Indemnification Expenses 7.10(a) Indemnified Parties 7.10(a)(i) Initial Limited Partner 7.20 Intervening Event 7.3(f) Letter of Transmittal 3.4(b) LP Merger Recitals LP Merger Consideration 3.1(c)(i) LP Merger Effective Time 2.1(d) Maximum Amount 7.10(c) Merger Consideration 3.1(c)(i) Merger Sub 1 Preamble Merger Sub 2 Preamble Merger Sub 3 Preamble Merger Subsidiaries Preamble Mergers Recitals MGP Preamble New Plans 7.13(b) Notice Period 7.3(e)(i) Old Plans 7.13(b)(i) Opco Election 3.3(a) Opco Election Consideration 3.1(c)(i)(C) Opco Election Units 3.1(c)(i)(C) Outside Date 9.1(f) Owned Real Property 5.14(a) Parent Preamble Parent Award 3.5(a) Parent Board Recitals Parent Disclosure Letter 4.2(iii) Parent Entities Preamble Parent Financial Statements 6.8(b) Parent Material Adverse Effect Article VI Parent Opco Preamble Parent Opco Tax Protection Agreement 4.2 Contingent Payment 1.2(b2.1(e) CTAs 2.9(bParent Permits 6.12(b) Damages 6.1 DOJ 4.3(aParent Preferred Stock 6.2(a) Domain Name Assignment Agreement 1.3(b)(viParent SEC Documents Article VI Partnership Preamble Partnership Board Recommendation 7.2(b) Downward Adjustment Amount 1.4(c)(iPartnership Change in Recommendation 7.3(d)(i)(D) Draft Allocation 8.5 Electronic Delivery 10.7 Partnership Disclosure Letter 4.1(iii) Partnership Employee Benefit Plan 2.16(a5.18(a) Employment Practices 2.15(bPartnership Entities Preamble Partnership Equity Plans 3.5(a) Environmental Laws 2.19 Environmental Partnership Income Tax Returns 7.18(f) Partnership Intellectual Property 5.19 Partnership Material Adverse Effect Article V Partnership Material Agreement 5.12(a) Partnership Meeting 5.6(ii)(A) Partnership Organizational Documents 5.1(a) Partnership Parties 10.14 Partnership Permits 2.19 ERISA 2.16(a5.11(b) Estimated Net Working Capital 1.2(ePartnership Property 5.14(b) 68 Excluded Assets 1.1(bPartnership Proxy Statement 5.6(ii)(A) Excluded Liabilities 1.1(dPartnership Related Party Agreement 5.20 Partnership Related Persons 9.4(f) FDA 2.13(bPartnership Restricted Unit 3.5(a) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b) Material Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller Partnership SEC Documents Article II V Partnership Subsidiary Documents 5.1(a) Partnership Units 5.2(a) Payoff Letter 7.17(c) Proceedings 5.15 Proposed Allocation 7.18(h) Qualified REIT Subsidiary 6.7(ii)(A)(ii) Registration Statement 6.7(ii)(A) Regular Merger Consideration Allocation 7.18(h) Seller Representative 7.18(f) Stock Election 3.3(a) Stock Election Consideration 3.1(c)(i)(B) Stock Election Units 3.1(c)(i)(B) Superior Proposal 7.3(i)(ii) 18 Support Agreement Recitals Surviving EGP Entity 2.1(b) Surviving MGP Entity 2.1(a) Surviving Partnership Entity 2.1(c) Tax Merger Consideration Allocation 7.18(h) Taxable REIT Subsidiary 6.7(ii)(A)(iii) Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(a) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii9.4(e) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(ii7.18(b)

Terms Defined Elsewhere. The following is a list of additional terms are defined elsewhere used in this Agreement, as indicated belowAgreement and a reference to the Section hereof in which such term is defined: 2017 Bonuses 9.3(aTerm Section AAA Section 9.3(b) Acquired Assets 1.1(aAdjustment Event Section 2.6 Aggregate Company Consideration Section 2.2(b) Aggregate Threshold 6.5(b)(iiN.Z. Consideration Section 2.1(b) Agreed Amount 6.3(bAggregate U.S. Consideration Section 2.1(a) Agreement Preamble Antitrust Approvals 4.3(bArbitrator Section 9.3(b) Applicable Cap Amount 6.5(b)(iAustralian Business Number Section 4.12(a) Assigned Contracts 1.1(a)(iiiAustralian Company Preamble Australian Indemnification Obligations Section 9.2(a)(i) Assumed Liabilities 1.1(cBlue Sky Laws Section 4.17 Cash Consideration Section 2.4(b) Assumption Agreements 1.1(cCash Percentage Section 2.4(a) Xxxx of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee CERCLA Section 4.13 Claim Notice Section 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a) Section 3.1 Closing Date 1.3(aSection 3.1 Company Cap Section 9.5(b) Closing Net Working Capital 1.4(aCompany Marks Section 4.20(b) Closing Statement 1.4(aCompany Patents Section 4.20(c) COBRA 9.3(fCompany Percentage Interest Section 2.2(b) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(bCompany Registered Copyrights Section 4.20(d) Confidentiality Agreement 4.2 Contingent Payment 1.2(bCompany Registered IP Section 4.20(g) CTAs 2.9(bCompany Shareholders Recitals Company Shares Recitals Company Software Section 4.20(l) Copyrights Section 4.20(a) Damages 6.1 DOJ 4.3(aSection 9.2(a) Domain Name Assignment Disposition Section 6.9 Dispute Notice Section 9.3(b) Double Taxation Agreement 1.3(b)(viSection 4.12(a) Downward Adjustment Effective Period Section 6.2(d) Employee Loans Section 4.8(a) Escrow Account Section 2.5 Escrow Agent Section 2.5 Escrow Amount 1.4(c)(iSection 2.5 Escrow Shares Section 2.5 Escrow Value Section 9.6 Foreign Status Certificate Section 3.2(n) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) 68 Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(bGST Section 4.12(a) Hazardous Substances 2.19 Healthcare Laws 2.13(aMaterials Section 4.13 Holder Section 6.2(f)(iii) HSR Act 2.4(bInbound License Agreements Section 4.20(i) Indemnified Party 6.3(aSection 9.3(a) Indemnitor Section 9.3(a) Intellectual Property Section 4.20(a) Lock-up Section 6.9 Lock-up Period Section 6.9 Marks Section 4.20(a) Mask Works Section 4.20(a) Material Contracts Section 4.8(a) Net Cash Deficit Section 2.7(b) Net Cash Estimate Section 2.7(a) N.Z. Company Preamble N.Z. Purchase Price Section 2.1(d) N.Z. Shareholders Recitals N.Z. Shares Recitals Net Cash Estimate Section 2.7(a) OSR Section 6.14 Outside Date Section 8.1(b) Parent Preamble Parent SEC Documents Section 5.5 Patents Section 4.20(a) Personal Element Section 4.20(p) Privacy Policies Section 4.20(p) Proceeding Section 4.18 Purchaser Preamble Purchaser Indemnified Parties Section 9.2(a) Real Property Section 4.5(c) Registration Indemnified Party Section 6.2(g)(iii) Registration Indemnifying Party 6.3(aSection 6.2(g)(iii) Inquiry 4.7(aRegistration Statement Section 6.2(a) IP Assignment Agreements 1.3(b)(viiShare Consideration Section 2.4(b) IP License Agreement 1.3(b)(ivShare Percentage Section 2.4(a) Lease 2.8(b) Leased Real Property 2.8(b) Material Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Shareholder Indemnified Parties 6.2 Seller Related Parties 7.2(b)(vSection 9.2(b) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(iShares Section 2.3 Software Section 4.20(l) Seller Trademarks 9.6 Shire Milestone Payment 9.4(aTax Section 4.12(a) Specified Milestone Payment 9.4(aTax Return Section 4.12(a) Straddle Period 8.1(b)(iTaxable Section 4.12(a) Sublease 1.3(b)(xiTaxes Section 4.12(a) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(aThreshold Amount Section 9.5(a) Third Party IP 2.9(bTrade Secrets Section 4.20(a) Trademark Assignment Agreement 1.3(b)(viiTransaction Fees Section 10.12 U.S. Company Preamble U.S. Purchase Price Section 2.1(b) Transfer Taxes 8.1(aU.S. Shareholder Recitals U.S. Shares Recitals Unique Identifying Number Section 4.20(p) Transferred Accounts Receivable 1.1(a)(xivUnstamped Transfers Section 6.14 User Data Section 4.20(p) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(iiViolation Section 6.2(g)(i)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(bTerm Section Action 3.5(g) Agreement Preamble Antitrust -12- Allocation Methodology 2.9(a) Allocation 2.9(b) Approvals 4.3(b2.10(a) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iiiAsset Purchase Recitals Assignment Agreement and Xxxx of Sale 2.8(a)(v) Assumed Liabilities 1.1(c2.6 Bankruptcy Code 2.13(h) Assumption Agreements 1.1(c) Xxxx of Sale 1.3(b)(iiiBasket 7.6(a) Business Benefit Plans 2.16(aContracts 2.4(a) Business Employee 9.3(aCovered Person 5.9 Business Litigation Controlling Party 5.6(b) Buyer Preamble Buyer FDA Letters 5.3(dBusiness Litigation 5.6(a) Buyer Group 1.1(aBusiness Permits (b) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(aCap 7.6(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a7.4(c) Closing Date 1.3(a) 2.3 Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b2.3 Consent 5.12(a) Confidentiality Agreement 4.2 Contingent Payment 1.2(b5.2(a) CTAs 2.9(bControlling Party 7.4(b)(iii) Damages 6.1 DOJ 4.3(aCovered Activities 3.10(c) Domain Name Assignment Agreement 1.3(b)(viCovered Protected Information 3.10(c) Downward Adjustment Amount 1.4(c)(iDx Copyright License 2.13(a)(iii) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(aDx Framework Source Code 2.13(a)(iii) Employment Practices 2.15(bDx Infringement 2.13(f)(iv) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(aDx System License 2.13(a)(ii) Estimated Net Working Capital 1.2(eDx Test License 2.13(a)(i) 68 Enforceability Limitations 3.2(b) Excluded Assets 1.1(b2.5 Expiration Date 7.1(a) Excluded Liabilities 1.1(dForeign Closing Documents 2.8(a)(vi) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a3.5(g) HSR Act 2.4(bHIPAA 3.5(g) Historical Financial Statements 7.4(a) Indemnified Party 6.3(a7.4(a) Indemnifying Party 6.3(a7.4(a) Inquiry 4.7(aIndependent Accounting Firm 2.9(b) IP Assignment Agreements 1.3(b)(viiContracts 3.9(i) IP Liability Assumption 7.4(b)(i) License Recitals Material Customer Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b3.12(a) Material Contract 2.10(aCustomer Agreement 3.13(a) Material Customers 2.11 Customer 3.12(a) Material Suppliers 2.11 New Buyer Employee 9.3(aDistributor or Reseller Agreement 3.13(c) Material Distributor 3.13(c) Milestone Payment Date 2.2(c)(i) Milestone Payment 2.2(b)(i) -13- [***] Confidential Treatment Requested - Milestone Trigger 2.2(b)(i) Mutual Transfer Agreement 5.4(c) NanoString Board of Directors 3.2(a) NanoString Indemnified Parties 7.3 NanoString Indemnified Party 7.3 NanoString Other Systems 2.13(a) NanoString Preamble NIH Assignment 5.1 NIH License 5.1 NIH Outside Date 5.1 Non-Controlling Party 7.4(b)(iii) Non-Compete Period 9.9(aPaying Party 6.3(b) Non-Contingent Bonuses 9.3(cRegulatory Approvals 2.10(b) Non-Solicit Period 9.9(bTransferable Asset 2.10(a) Notice of Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii7.4(d) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(vPEO 5.4(c) Permits 1.1(a)(ivProduct Licenses 3.5(c) Pre-Closing Period 4.1(aPurchased Assets 2.4 Purchaser’s Allocation Notice 2.9(b) Purchaser’s Allocation 2.9(b) Registered Business IP 2.9(aLicensed Intellectual Property 3.9(a) Regulatory Authority 2.13(bPermits 5.1(a) Regulatory Filings 4.3(aRelevant Matters 8.8(a) Reimbursement Amount 9.4(cReplaced Distributor Contracts 2.10(b) Related Agreements 2.3 Restricted Names 9.5 Safety Notice Replaced Distributor Relationship 2.10(b) Replacement Distributor Contracts 2.10(b) Replacement NIH License Agreement 5.1 Retained Liabilities 2.7 Review Committee 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(aStockholders 3.2(a) Straddle Period 8.1(b)(iTax 6.3(b) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Third-Party Claim 6.3(aNotice 7.4(a) Third Third-Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(viiClaim 7.4 Transactions Recitals Transfer Claimant 5.4(d) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi6.3(a) Transferred Permits 1.1(a)(iv2.4(d) Transition Services Agreement 1.3(b)(xPeriod 2.10(b) Upfront Payment 1.2(aUnilateral Settlement 7.4(b)(iii) Upward Adjustment Amount 1.4(c)(ii)Universal Panel 2.13(a) Update Report 2.2(c)(ii) Veracyte Indemnified Parties 7.2 Veracyte Indemnified Party 7.2 Veracyte SEC Documents 4.6(a) Veracyte Preamble -14- [***] Confidential Treatment Requested -

Terms Defined Elsewhere. The Each of the following terms are is defined elsewhere in this Agreement, as indicated belowthe Section set forth opposite such term: 2017 Bonuses 9.3(aTerm Section 401(k) Acquired Assets 1.1(aTermination Date 8.03(c) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(bAcceptable Confidentiality Agreement 6.02(b) Agreement Preamble Antitrust Approvals 4.3(bAncillary Scheme Documentation Section 3.01(a)(ii) Applicable Cap Amount 6.5(b)(iApple Preamble Apple Adverse Recommendation Change 6.02(a) Assigned Contracts 1.1(a)(iiiApple Approval Time 6.02(b) Assumed Liabilities 1.1(cApple Board Recitals Apple Board Recommendation 4.02(b) Assumption Agreements 1.1(cApple Organizational Documents 4.01 Apple Payment Fund 2.01(b) Xxxx of Sale 1.3(b)(iiiApple Permits 4.12 Apple Registered IP 4.19(a) Business Benefit Plans 2.16(aApple Regulatory Agency 4.14(a) Business Employee 9.3(aApple Regulatory Permits 4.14(a) Buyer Preamble Buyer FDA Letters 5.3(dApple SEC Documents 4.07(a) Buyer Group 1.1(aBankruptcy and Equity Exceptions 4.02(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(aCapitalization Date 4.05(a) Claim Notice 6.3(b) Claimed Amount 6.3(bCash Consideration 2.01(a) Closing 1.3(a) 1.02 Closing Date 1.3(a1.02 Continuing Employees 8.03(a) Closing Net Working Capital 1.4(aCourt Documentation 3.01(a)(viii) Closing Statement 1.4(aCourt Order 1.03 CVR 2.01(a) COBRA 9.3(fCVR Agreement Recitals Depositary Custodian 2.01(b) Commercial Business Introduction Commercial Business Balance Sheet Effect Material Adverse Effect definition Effective Time 1.03 EMA Section 4.14(e) End Date 2.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) 68 Excluded Assets 1.1(b10.01(b)(i) Excluded Liabilities 1.1(dBenefits Section 8.03(a) FDA 2.13(b4.14(a) Final Allocation 8.5 Final Net Working Capital 1.4(b)(ivFDCA 4.14(a) FSA Balances 9.3(aForms of Proxy 3.01(a)(ii) FSA Participants 9.3(aIn-the-Money Unvested Apple Share Option 2.02(c) FTC 4.3(a2.01(b) Fundamental Representations 6.4(aIn-the-Money Vested Apple Share Option Section 2.02(c) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(bSection 2.01(d) Indemnified Party 6.3(a7.01(b) Indemnifying Party 6.3(aLabor Agreement 4.15(a)(iii) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(bLeases 4.21 Material Contract 4.15(a) Material Contract 2.10(aSupplier 4.27 Maximum Amount 7.01(c) Material Customers 2.11 Material Suppliers 2.11 Nasdaq 4.03 New Buyer Employee 9.3(aPlans 8.03(b) No-Vote Termination Fee Section 10.03(a)(iii) Non-Compete Period 9.9(aU.S. Plan 4.17(j) Non-Contingent Bonuses 9.3(cOld Plans 8.03(b) Non-Solicit Period 9.9(bOrdinary Termination Fee 10.03(a)(ii) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(iiOther Required Filing 3.01(a)(iii) Parties Preamble Party Paying Agent 2.01(b) Payoff Letter Section 8.08 Per ADS Cash Consideration 2.01(a) Per ADS CVR 2.01(a) Per ADS Transaction Consideration 2.01(a) PHSA 4.14(a) Proxy Statement 3.01(a)(i) Protected Data Section 4.20(c) Purchaser Preamble Patent Assignment Agreement 1.3(b)(vPurchaser Board Recitals Purchaser Organizational Documents Section 5.04 Real Properties 4.21 Regulation S-K 4.07(g) Permits 1.1(a)(ivRelevant Participant Section 2.02(i) Pre-Closing Period 4.1(aRetention Award Section 8.03(h) Registered Business IP 2.9(aRetention Pool Section 8.03(h) Regulatory Authority 2.13(bRights Agent Recitals Scheme Document Annex 3.01(a)(i) Regulatory Filings 4.3(aSecond Request 8.02(c) Reimbursement Amount 9.4(cSenior Counsel 3.01(a)(x) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(dTail Coverage Section 7.01(c) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(aTakeover Code Section 4.26 Transaction Recitals Transaction Consideration 2.01(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(gTransaction Documentation Section 3.01(a)(iv) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(a) Straddle Period 8.1(b)(i) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(a) Third Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(vii) Transaction Litigation 6.03 Transfer Taxes 8.1(a11.04 Transition Award Section 2.02(i) Transferred Accounts Receivable 1.1(a)(xivTransitional Cash Plan Section 2.02(i) Transferred Inventory 1.1(a)(xiUnvested Apple PSU Section 2.02(g) Transferred IP 1.1(a)(ivUnvested Apple RSU Section 2.02(f) Transferred IP Agreements 2.9(bUnvested Awards Section 2.02(i) Transferred IP Documentation 1.1(a)(viUnvested Cash Consideration Section 2.02(j) Transferred Permits 1.1(a)(ivUnvested CVR Consideration Section 2.02(j) Transition Services Agreement 1.3(b)(xAnnex B FORM OF SCHEME OF ARRANGEMENT (see attached) Upfront Payment 1.2(aAnnex B FORM OF SCHEME OF ARRANGEMENT IN THE HIGH COURT OF JUSTICE CR - [2023] - [●] BUSINESS AND PROPERTY COURTS OF ENGLAND AND WALES COMPANIES COURT (ChD) Upward Adjustment Amount 1.4(c)(iiIN THE MATTER OF ORCHARD THERAPEUTICS PLC and IN THE MATTER OF THE COMPANIES ACT 2006 SCHEME OF ARRANGEMENT (under Part 26 of the Companies Act 2006) between ORCHARD THERAPEUTICS PLC and THE SCHEME SHAREHOLDERS (as hereinafter defined)

Terms Defined Elsewhere. The following terms are defined elsewhere in this Agreement, as indicated below: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(bTerm Section Action 3.5(g) Agreement Preamble Antitrust Allocation Methodology 2.9(a) Allocation 2.9(b) Approvals 4.3(b2.10(a) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iiiAsset Purchase Recitals Assignment Agreement and Xxxx of Sale 2.8(a)(v) Assumed Liabilities 1.1(c2.6 Bankruptcy Code 2.13(h) Assumption Agreements 1.1(c) Xxxx of Sale 1.3(b)(iiiBasket 7.6(a) Business Benefit Plans 2.16(aContracts 2.4(a) Business Employee 9.3(aCovered Person 5.9 Business Litigation Controlling Party 5.6(b) Buyer Preamble Buyer FDA Letters 5.3(dBusiness Litigation 5.6(a) Buyer Group 1.1(aBusiness Permits (b) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(aCap 7.6(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a7.4(c) Closing Date 1.3(a) 2.3 Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b2.3 Consent 5.12(a) Confidentiality Agreement 4.2 Contingent Payment 1.2(b5.2(a) CTAs 2.9(bControlling Party 7.4(b)(iii) Damages 6.1 DOJ 4.3(aCovered Activities 3.10(c) Domain Name Assignment Agreement 1.3(b)(viCovered Protected Information 3.10(c) Downward Adjustment Amount 1.4(c)(iDx Copyright License 2.13(a)(iii) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(aDx Framework Source Code 2.13(a)(iii) Employment Practices 2.15(bDx Infringement 2.13(f)(iv) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(aDx System License 2.13(a)(ii) Estimated Net Working Capital 1.2(eDx Test License 2.13(a)(i) 68 Enforceability Limitations 3.2(b) Excluded Assets 1.1(b2.5 Expiration Date 7.1(a) Excluded Liabilities 1.1(d-13- Foreign Closing Documents 2.8(a)(vi) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a3.5(g) HSR Act 2.4(bHIPAA 3.5(g) Historical Financial Statements 7.4(a) Indemnified Party 6.3(a7.4(a) Indemnifying Party 6.3(a7.4(a) Inquiry 4.7(aIndependent Accounting Firm 2.9(b) IP Assignment Agreements 1.3(b)(viiContracts 3.9(i) IP Liability Assumption 7.4(b)(i) License Recitals Material Customer Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b3.12(a) Material Contract 2.10(aCustomer Agreement 3.13(a) Material Customers 2.11 Customer 3.12(a) Material Suppliers 2.11 New Buyer Employee 9.3(aDistributor or Reseller Agreement 3.13(c) Material Distributor 3.13(c) Milestone Payment Date 2.2(c)(i) Milestone Payment 2.2(b)(i) Milestone Trigger 2.2(b)(i) Mutual Transfer Agreement 5.4(c) NanoString Board of Directors 3.2(a) NanoString Indemnified Parties 7.3 NanoString Indemnified Party 7.3 NanoString Other Systems 2.13(a) NanoString Preamble NIH Assignment 5.10 NIH License 5.10 NIH Outside Date 5.10 Non-Controlling Party 7.4(b)(iii) Non-Compete Period 9.9(aPaying Party 6.3(b) Non-Contingent Bonuses 9.3(cRegulatory Approvals 2.10(b) Non-Solicit Period 9.9(bTransferable Asset 2.10(a) Notice of Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii7.4(d) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(vPEO 5.4(c) Permits 1.1(a)(ivProduct Licenses 3.5(c) Pre-Closing Period 4.1(aPurchased Assets 2.4 Purchaser’s Allocation Notice 2.9(b) Purchaser’s Allocation 2.9(b) Registered Business IP 2.9(aLicensed Intellectual Property 3.9(a) Regulatory Authority 2.13(bPermits 5.1(a) Regulatory Filings 4.3(aRelevant Matters 8.8(a) Reimbursement Amount 9.4(cReplaced Distributor Contracts 2.10(b) Related Agreements 2.3 Restricted Names 9.5 Safety Notice -14- Replaced Distributor Relationship 2.10(b) Replacement Distributor Contracts 2.10(b) Replacement NIH License Agreement 5.10 Retained Liabilities 2.7 Review Committee 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation 4.7(a) Seller Disclosure Letter Article II 69 Seller FDA Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties 6.2 Seller Related Parties 7.2(b)(v) Seller SEC Documents Article II Seller Termination Fee 7.2(b)(i) Seller Trademarks 9.6 Shire Milestone Payment 9.4(a) Specified Milestone Payment 9.4(aStockholders 3.2(a) Straddle Period 8.1(b)(iTax 6.3(b) Sublease 1.3(b)(xi) Supply Agreements 4.6 Tax Claim 8.4 Third Third-Party Claim 6.3(aNotice 7.4(a) Third Third-Party IP 2.9(b) Trademark Assignment Agreement 1.3(b)(viiClaim 7.4 Transactions Recitals Transfer Claimant 5.4(d) Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi6.3(a) Transferred Permits 1.1(a)(iv2.4(d) Transition Services Agreement 1.3(b)(xPeriod 2.10(b) Upfront Payment 1.2(aUnilateral Settlement 7.4(b)(iii) Upward Adjustment Amount 1.4(c)(ii)Universal Panel 2.13(a) Update Report 2.2(c)(ii) Veracyte Indemnified Parties 7.2 Veracyte Indemnified Party 7.2 Veracyte SEC Documents 4.6(a) Veracyte Preamble